https://www.selleckchem.com/products/ps-1145.html
4% in the anti-TNF therapy group, and 0% and 40.7% in the surgery group, respectively (P=0.02. Multivariable Cox regression analysis showed that anti-TNF therapy was associated with a lower risk of rebleeding compared with CMT (hazard ratio, 0.303; 95% confidence interval, 0.108-0.849; P=0.023). In CD patients with acute severe LGIB, anti-TNF therapy may reduce the risk of rebleeding compared with CMT. Although surgery is considered effective in preventing early rebleeding, concomitant anti-TNF therapy may be helpful in further loweri
Like
Comment
Share
